Navigation Links
Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Date:11/18/2008

pany participated in the China's National R&D Program's selection and evaluation process. Sinovac was selected by the government to take charge of the research and development program for the varicella (chickenpox) vaccine. As an acute infectious disease, varicella often breaks out among the pediatric population and can lead to serious conditions such as pneumonia, encephalitis, and even death. This disease leads to serious symptoms among adult as well. The fatality rate in adults is as high as 30-40 times that of children between 5-9 years old. According to a report by the Children Hospital of Shanghai, current incidence rate among children is four times greater than rates reported in the 1980s. The domestic market in China is in a development phase with an annual demand of 10 million doses. Once the vaccine is successfully launched, Sinovac would provide the Chinese market with a new vaccine against varicella and the herpes zoster virus.

During the third quarter, Sinovac advanced the development of its split pandemic influenza vaccine. The Company completed volunteer enrollment and dosing in its Phase II double-blind trial of the split pandemic influenza vaccine. The second shot was administered to 472 healthy volunteers in September, inclusive of 263 adolescents, 138 pediatrics and 71 geriatrics. The vaccination process to volunteers has been completed and the Company is currently collecting data and preparing the analysis. It is anticipated that the preliminary results will be available in early 2009.

In October 2008, Sinovac was named to the Deliotte Technology Fast 50 China 2008 based on its high growth rate of 290% over the past three years. The ranking recognizes the 50 fastest growing life sciences, technology, media and telecommunications in China.

Conference Call Details

The Company will host a conference call on Tuesday, November 18, 2008 at 8:00 p.m. ET to review
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac Named to Deloitte Technology Fast 50 China
2. Sinovac to Participate in Two Upcoming Investor Conferences
3. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
4. Sinovac Biotech Holds 2007 Annual General Meeting
5. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
7. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
8. Sinovac Adjourns Annual General Meeting
9. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
10. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that the ... Russia , India and ... in 2013, roughly equal to the size of the ... BRIC market will experience much faster growth as a result of ... Other key findings from Decision Resources Group,s coverage of ...
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
(Date:8/20/2014)... 2014 The 6th Annual Arrowhead ... on October 29-30 in San Francisco, CA. This year’s ... government researchers and clinicians focused on addressing and solving ... In the twelve years since the sequencing of the ... introduced with pharmacogenetic information in the label and molecular ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3PAREXEL International To Present At Baird Healthcare Conference 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... ON , Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences ... financial results for the second quarter of fiscal 2010, ended ... numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., ... during the second quarter," said David Allan , Chairman ...
... , DENVER and NEW ORLEANS , Feb. ... worldwide developer and marketer of diagnostic test kits, and Tulane ... to combat viral hemorrhagic fever (VHF), an effort that will generate ... the life of the contract. , The National Institutes of ...
... , Feb. 8 Neurocrine Biosciences, Inc. (Nasdaq: ... Ph.D. to its Board of Directors effective immediately. He is the ... Executive Chairman of Biogen Idec, Inc. , "We are very pleased ... said Joseph A. Mollica , Ph.D., Chairman of the Board ...
Cached Biology Technology:YM BioSciences reports second quarter 2010 operational and financial results 2YM BioSciences reports second quarter 2010 operational and financial results 3YM BioSciences reports second quarter 2010 operational and financial results 4YM BioSciences reports second quarter 2010 operational and financial results 5YM BioSciences reports second quarter 2010 operational and financial results 6YM BioSciences reports second quarter 2010 operational and financial results 7YM BioSciences reports second quarter 2010 operational and financial results 8YM BioSciences reports second quarter 2010 operational and financial results 9YM BioSciences reports second quarter 2010 operational and financial results 10YM BioSciences reports second quarter 2010 operational and financial results 11YM BioSciences reports second quarter 2010 operational and financial results 12Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors 2
(Date:8/20/2014)... The sweet and salty aroma of sunscreen and seawater ... are now reporting that the idyllic beach vacation comes ... off skin and into the sea, they can become ... are the main course for many other marine animals. ... Science & Technology . , Antonio Tovar-Sanchez and David ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... Virginia Tech,s Wu Feng has built upon a National ... in the Cloud" program, and synergistically complemented it with ... the Air Force on "big computing" for mini-drones and ... Institutes of Health on "big data" for the life ... aspects from each grant, he was able to tell ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... discovered that very small chemical changes to dietary flavonoids cause ... for their impact on the human immune system., Plants are ... an average leaf for example, produces around 20,000. Many ... are already known to have medicinal properties with effects on ...
... and government, industry and health professionals will gather in ... the research supporting the health benefits of mushrooms ... produce aisle and often thought of as a vegetable ... The Mushrooms and Health Summit, held at the ...
... cholesterol levels and reducing the risks of cardiovascular disease, but ... The FASEB Journal suggests that they may extend ... which telomeres shorten, a key factor in the natural aging ... of statins, as an anti-aging therapy. "By telomerase activation, ...
Cached Biology News:Little changes -- large effects 2World's scientists, researchers and nutrition experts convene to explore the benefits of mushrooms 2
...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
... Point Osmometer for 10 L sample. ... including pediatric, neonatal, geriatric, general adult, ... Calibration with 2 or 3 user-selected ... and software for statistical analysis and ...
Biology Products: